Eledon Pharmaceuticals, Inc. (ELDN) Dividend History

Company News

• Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

  Eledon Pharmaceuticals announced that its investigational anti-CD40L antibody, tegoprubart, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a transplanted kidney from a genetically modified pig. The procedure was performed at Massachusetts General Hospital in collaboration with partner eGenesis.

  GlobeNewswire Inc.
• 4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com

  The article discusses four small-cap stocks that offer high risk and high reward potential as investors rotate their portfolios. The stocks are from the biotech and electric vehicle sectors, with analysts seeing significant upside but also inherent risks.

  Investing.com

  Featured Companies: ABOS BLNK
• Are Medical Stocks Lagging DaVita (DVA) This Year?

  Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

  Zacks Investment Research

  Featured Companies: DVA
• Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence

  Tuesday, Eledon Pharmaceuticals Inc (NASDAQ:ELDN) announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with tegoprubart for the prevention of pancreatic islet cell transplant rejection in type 1 diabetes patients. The company also reported updated data from its ongoing Phase 1b trial as of April 2024 from 13 participants, demonstrating that tegoprubart is generally safe and well-tolerated and supports tegoprubart’s potential to protect organ function in patients undergoing kidney transplantation. Aggregate mean estimated glomerular filtration rate (eGFR) – a measure of kidney function – measured above 60 mL/min/1.73m2 at all reported time points after day 30. Two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year. To date, three subjects discontinued the ...Full story available on Benzinga.com

  Benzinga
• Penny Stocks To Buy Now? 4 To Watch This Week

  Penny stocks to watch this week. The post Penny Stocks To Buy Now? 4 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: GFAI GRAB MULN